Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study

Publication | Closed Access

DOI

Citations

References

2018

Year

Ekaterini Christina Tampaki, Athanasios Tampakis, Constantinos Alifieris, Dimitrios Krikelis, Anastasia Pazaiti, Michalis Kontos, Dimitrios T. Trafalis

Clinical Drug Investigation

Breast OncologyMedicineCancer ManagementPharmacologyLiposomal DoxorubicinBreast CancerPharmacotherapyGrade IiiPaclitaxel CombinationCancer TreatmentOncologyGynecology Oncology